

Table 1—Components of the metabolic syndrome at baseline

Component	Definition	n	Mean \pm SD	% Elevation
Elevated glycemia				6.9
Glucose	≥ 140 mg/dl	4,453	99.3 ± 16.3	2.5
Glycosylated Hemoglobin	$\geq 7\%$	4,453	5.8 ± 0.7	5.4
High blood pressure				18.4
Systolic	≥ 160 mmHg	4,451	131.5 ± 20.3	9.1
Diastolic	≥ 90 mmHg	4,451	77.5 ± 11.0	13.1
High-risk lipid levels				82.7
Serum total cholesterol	≥ 200 mg/dl	4,452	233.5 ± 44.0	77.9
Serum HDL cholesterol	< 35 (men), < 39 (women) mg/dl	4,448	52.7 ± 17.7	15.9
Lipid ratio (Total/HDL)	> 5.7 (men), > 5.1 (women)	4,447	4.9 ± 1.9	33.4
Elevated BMI	> 30 kg/m ²	4,423	28.5 ± 5.3	33.2
Elevated uric acid level	> 7.0 mg/dl	4,453	6.0 ± 1.9	27.0
Proteinuria	≥ 30 mg/dl	4,437	—	3.3

ture to obtain serum for total cholesterol (18), HDL cholesterol (19), glycosylated hemoglobin (20), glucose (21), and uric acid (22). These tests, except for serum uric acid, were repeated at the 5-year follow-up. Subjects were not requested to fast. Proteinuria was defined as 30 mg/dl or more, as tested by a dipstick on a casual urine specimen that was collected at the time of the study examination.

Diabetes was defined as a previous history of diabetes (treated with insulin and/or oral hypoglycemic agents and/or diet) or hyperglycemia. Hyperglycemia here is defined as glycosylated hemoglobin > 2 SDs above the mean for the appropriate age-sex group at the given examination or a casual blood glucose level > 200 mg/dl (1.1 mmol/l). Newly diagnosed diabetes was defined as no previous history of diabetes in the presence of glycosylated hemoglobin that was > 2 SDs above the mean for the appropriate age-sex group. There were 50 such persons. A total of 446 persons had diabetes at the time of the baseline examination. We excluded data from these individuals. Our definitions of the components of the metabolic syndrome were adapted from Alberti and Zimmet (7). The criteria they describe are impaired glucose intolerance, including frank diabetes or insulin resistance, and two or more of a list including elevated arterial pressure, elevated plasma triglyceride and/or low HDL cholesterol levels, central obesity or high BMI, and microalbuminuria. They indicate that other components have been described (e.g., hyperuricemia), but they do not include these in their definition. The components we included were level of

glycemia, hypertension, serum total cholesterol level, serum HDL cholesterol level, ratio of serum total cholesterol to HDL cholesterol, serum uric acid level, obesity, and proteinuria (Table 1).

SAS statistical software was used to calculate χ^2 statistics, logistic regression, and Pearson correlations. Tests of trend were calculated by the Mantel-Haenszel method (23).

RESULTS — The baseline distribution of components of the metabolic syndrome that we have used to define elevated risk are shown in Table 1. Elevated serum total cholesterol and elevation of the ratio of total to HDL cholesterol (lipid ratio) derived from it are the most common risk factors, followed by elevated BMI, uric acid level, and blood pressure. For two of the lipid variables (serum HDL cholesterol and ratio of total to HDL cholesterol), different cutpoints are used to define “elevated” values for women and men. Elevated glycosylated hemoglobin level, albuminuria, and elevated blood glucose level were less common. For the remainder of this study, we discuss only elevated glycemia (either elevated serum glucose or elevated glycosylated hemoglobin), high-risk lipid levels (elevated total cholesterol, low HDL cholesterol, or elevated lipid ratio), and high blood pressure risk factor (high systolic or high diastolic blood pressure). The pairwise relationships of components of the metabolic syndrome within subjects are shown in Table 2. Many are significantly associated with the others. Correlation coefficients for continuously measured variables, in general, reflected the find-

ings from the dichotomous analyses (correlations not shown in Table 2). Strongest correlations were between the lipid ratio and BMI (0.25), lipid ratio and uric acid level (0.34), BMI and uric acid level (0.31), and uric acid and HDL cholesterol levels (-0.30).

The population was examined 5 years after the baseline examination, at which time information about incident myocardial infarction, stroke, and angina during that interval was obtained. The incidences were 3.0% for myocardial infarction, 1.5% for stroke, and 4.0% for angina. These diagnoses are considered collectively as CVD. Incidences of CVD for each component are shown in Table 3. Because odds ratios were influenced by age and sex, the odds ratios are adjusted for these components. The greatest risks are associated with elevations in level of glycemia and presence of proteinuria.

We computed the relative risk of developing CVD by the number of these components at baseline (Table 4). The risk of incident CVD is approximately six times greater when four or more components are present, compared with when none of the components are present. Contributions of the individual components to clusters of factors associated with increased risk of CVD are shown in Table 5. For combinations of risk factors (1, 2, etc.), elevated glycemia occurred in 1.0% of those with one component, 6.1% of those with two components, 14.2% of those with three components, and 40% of those with four or more components. High-risk lipid levels occurred most commonly in the combinations of compo-

Table 2—Pairwise relationships of components of the metabolic syndrome at baseline

Component		Elevated glycemia		High blood pressure		High-risk lipid levels		Elevated BMI		Elevated uric acid level		Presence of proteinuria	
		%	P value	%	P value	%	P value	%	P value	%	P value	%	P value
Glycemia	Normal			18.0		82.3		32.2		25.8		3.2	
	Elevated			23.8	0.01	88.0	0.01	46.2	<0.001	43.5	<0.001	3.9	0.51
Blood pressure	Normal	6.4				82.1		30.3		25.6		2.6	
	Elevated	8.9	0.01			85.2	0.03	45.6	<0.001	33.3	0.001	6.5	<0.001
High-risk lipid levels	Absent	4.8		15.7				23.7		17.6		4.6	
	Present	7.4	0.01	19.0	0.03			35.2	<0.001	29	<0.001	3.0	0.03
BMI	Normal	5.6		15.0		80.2				20.2		3.0	
	Elevated	9.6	<0.001	25.4	<0.001	87.6	<0.001			40.5	<0.001	3.6	0.29
Uric acid level	Normal	5.4		16.8		80.5		27.0				2.5	
	Elevated	11.2	<0.001	22.7	<0.001	88.7	<0.001	49.9	<0.001			5.4	<0.001
Proteinuria	No	6.8		17.8		82.9		33.1		26.4			
	Yes	8.2	0.51	36.3	<0.001	76.0	0.03	37.3	0.29	44.5	<0.001		

nents that were associated with increased risk of CVD.

The relative risk of incident diabetes by each component is shown in Table 6. The measures of glycemia were most strongly related to incident diabetes; elevated BMI, high blood pressure, and elevated uric acid level also had significant relationships. Individuals with increasing numbers of risk factors are at increased risk of incidence of diabetes, such that those with four or more components are ~35 times as likely to develop the disease as those with none of the components at baseline (Table 7).

CONCLUSIONS— We have found that components of the metabolic syndrome, as we define them, in a population of individuals without diagnosed diabetes are relatively common and that they predict incident CVD and diabetes. The metabolic syndrome, originally described by Reaven (5), has been found in many ethnic groups (24). Insulin resistance may be the underlying pathophysiological basis of the syndrome. However, irrespective of understanding the specific metabolic relationships, the clinical importance of determining whether one, two, or more of these frequently measured components or variables closely related to them are most responsible for the link to subsequent macrovascular disease lies in whether they can be altered to reduce risk. Intervening directly on glycemia in people who at the moment do not carry a diagnosis of diabetes is probably not feasible. A more pragmatic approach might be to apply interventions aimed at altering

levels of some of the other components of the metabolic syndrome (BMI, blood pressure, and lipid levels) in an effort to forestall incident heart disease and diabetes. Treating obesity, blood pressure, and higher lipid levels is no easy matter either, but there likely would be benefits to many disease end points not examined here and to the quality of life if interventions on

these factors were successful. The recent Diabetes Prevention Trial (25) attests to the efficacy of an intervention to prevent diabetes based on altering these risk factors. Our data suggest the possibility that decreasing even one or two of the components of the metabolic syndrome may reduce the overall risk of incident CVD and diabetes. The components of the syn-

Table 3—Incidence of CVD by components of the metabolic syndrome

Component		n	Incidence (%)	Age- and sex-adjusted odds ratio (95% CI)		P value
Elevated glycemia	Normal	2,821	5.5			
	Elevated	150	14.0	2.31 (1.40, 3.82)		0.001
High blood pressure	Normal	2,464	5.8			
	Elevated	506	6.7	1.14 (0.77, 1.69)		0.50
High-risk lipid levels	Normal	535	3.4			
	Elevated	2,436	6.5	2.01 (1.21, 3.33)		0.01
Elevated BMI	Normal	1,983	5.6			
	Elevated	980	6.7	1.21 (0.88, 1.67)		0.24
Elevated uric acid level	Normal	2,257	4.8			
	Elevated	714	9.5	1.66 (1.19, 2.33)		0.003
Proteinuria	No	2,895	5.8			
	Yes	70	12.9	2.44 (1.16, 5.12)		0.02

Table 4—Incidence of CVD by number of components of the metabolic syndrome

No. of Components	n	Incidence (%)	Odds ratio (95% CI)		P value
0	318	2.5	1.0		
1	1,182	5.0	1.95 (0.91, 4.16)		0.08
2	885	6.1	2.05 (0.96, 4.40)		0.06
3	424	7.8	2.70 (1.22, 5.98)		0.01
4+	148	14.9	5.86 (2.51, 13.66)		<0.001

Table 5—Contribution of each component of the metabolic syndrome to number of components in subjects at baseline examination (n = 4,406)

No. of Components	n	Elevated glycemia (%)	Elevated blood pressure (%)	High-risk lipid levels (%)	Elevated uric acid level (%)	Elevated BMI (%)	Proteinuria (%)
0	418	0.0	0.0	0.0	0.0	0.0	0.0
1	1,689	1.0	2.9	87.2	3.3	5.2	0.5
2	1,335	6.1	22.3	92.4	31.8	43.9	3.5
3	704	14.2	38.5	96.9	67.3	77.7	5.4
4	260	40.0	74.6	98.5	90.4	92.3	18.5

drome are not only common, but the correlations among them are, in many cases, significant. It may be that intervention on one of a pair of components may have an effect on the other. Therefore, decreasing BMI may have a beneficial effect on blood pressure, lipid levels, and uric acid level. It is possible that intervening on blood pressure may also have beneficial effects on the kidney, at least with respect to proteinuria. Although we can, at best, only

infer the possibility of such benefits, they are plausible.

We adapted, rather than adopted, the World Health Organization (WHO) criteria described by Alberti and Zimmet (7) for two reasons. The first is that our data were limited due to the study being initially designed primarily as a study of age-related eye disease. The second is that we were interested in the risks posed by the factors we examined in individuals from a

general population who did not have overt diabetes. Although our study design is not ideal for evaluating the impact of a strictly defined study of the predictive ability of the WHO (or National Cholesterol Education Program) (26) criteria, we believe that our findings complement such studies.

We note several limitations to our investigation. Participants at the second examination were younger, had slightly lower serum cholesterol levels, had lower total HDL cholesterol ratios, had lower serum uric acid levels, were less likely to have CVD, and were less likely to have hypertension than those who participated only in the baseline exam. Our diagnoses of CVD are by self-report. This may lead to over- or under-reporting. Mortality from CVD is not included, because at this time, we do not have these data. This likely results in an underestimate of cardiovascular events because of those who gave no history of the condition but died of it. At this time, we cannot estimate the effect of this on incidence of CVD, nor can we determine its effects on the risk factor analyses. Lastly, our population is middle-aged, predominantly white, and rural. Therefore, we cannot make inferences beyond a similar group. These limitations notwithstanding, we have found that components of the metabolic syndrome singly, and in combination, are common and precede incident CVD and diabetes. This is despite the fact that the levels of the components we defined as high risk were not very high. In addition, increased risk can be observed as soon as 5 years later. This heightens the importance of determining ways to intervene on some or all of the components and implementing such interventions promptly.

Table 6—Incidence of diabetes by components of the metabolic syndrome at baseline in Individuals without diabetes

Component		n	Incidence (%)	Age- and sex-adjusted odds ratio (95% CI)	P value
Elevated glycemia	Normal	3,108	2.0		
	Elevated	182	29.1	18.33 (12.15, 27.67)	<0.001
High blood pressure	Normal	2,729	3.2		
	Elevated	560	5.2	1.65 (1.07, 2.55)	0.02
High-risk lipid levels	Normal	586	2.4		
	Elevated	2,704	3.7	1.55 (0.88, 2.74)	0.13
Elevated BMI	Normal	2,184	1.9		
	Elevated	1,094	6.7	3.75 (2.54, 5.55)	<0.001
Elevated uric acid level	Normal	2,447	2.7		
	Elevated	843	5.9	2.02 (1.36, 3.01)	<0.001
Proteinuria	No	3,201	3.5		
	Yes	82	3.7	0.98 (0.30, 3.19)	0.98

Table 7—Incidence of diabetes by number of components of the metabolic syndrome

No. of Components	n	Incidence (%)	Odds ratio (95% CI)	P value
0	338	0.6	1.0	—
1	1,291	1.1	1.75 (0.39, 7.72)	0.47
2	977	3.9	5.99 (1.44, 24.98)	0.01
3	492	5.9	9.37 (2.22, 39.59)	0.002
4+	173	17.9	33.67 (7.93, 142.96)	<0.001

Acknowledgments—This work was supported by National Institutes of Health Grant EY06594 (to R.K. and B.E.K.K.).

References

1. Truett J, Cornfield J, Kannel W: A multivariate analysis of the risk of coronary heart disease in Framingham. *J Chron Dis* 20:511–524, 1967
2. Saito I, Folsom AR, Brancata FL, Duncan BB, Chambless LE, McGovern PG: Nontraditional risk factors for coronary

- heart disease incidence among persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) Study. *Ann Intern Med* 133:81–91, 2000
3. Farrand ME, Mojonier L: Nutrition in the Multiple Risk Factor Intervention Trial (MRFIT). *J Am Diet Assoc* 76:347–351, 1980
4. Klein R, Klein BEK, Cornoni JC, Maresky J, Cassel JC, Tyroler HA: Serum uric acid: its relationship to coronary heart disease risk factors and cardiovascular disease, Evans County, Georgia. *Arch Intern Med* 132:401–410, 1973
5. Reaven GM: Banting lecture 1988: role of insulin resistance in human disease. *Diabetes* 37:1595–1607, 1988
6. Kaplan NM: The deadly quartet: upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. *Arch Intern Med* 149:1514–1520, 1989
7. Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part I: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. *Diabet Med* 15:539–553, 1998
8. Boyko EJ, de Courten M, Zimmet PZ, et al: Features of the metabolic syndrome predict higher risk of diabetes and impaired glucose tolerance. *Diabetes Care* 23:1242–1248, 2000
9. Mykkanen L, Kuusisto J, Pyorala K, Laakso M: Cardiovascular disease risk factors as predictors of type 2 (non-insulin-dependent) diabetes mellitus in elderly subjects. *Diabetologia* 36:553–559, 1993
10. U.S. Dept. of Health, Education, and Welfare: *The Health Consequences of Smoking: A Report to the Surgeon General*. Washington, DC, U.S. Dept. of Health, Education, and Welfare, 1971 (HSM no. 71–7513)
11. Doll R, Peto R, Hall E, Wheatley K, Gray R: Mortality in relation to consumption of alcohol: 13 years' observations on male British doctors. *BMJ* 309:911–918, 1994
12. Paffenbarger RS Jr, Wing AL, Hyde RT: Physical activity as an index of heart attack risk in college alumni. *Am J Epidemiol* 108:161–175, 1978
13. Campbell JA, Palit CD: Total digit dialing for a small area census by phone. *Proceedings of the American Statistical Association Section on Survey Research Methods*. Alexandria, VA, ASA, 1988, p. 549–559
14. Klein R, Klein BEK, Linton KLP: Prevalence of age-related maculopathy: the Beaver Dam Eye Study. *Ophthalmology* 99:933–943, 1992
15. Klein R, Klein BEK, Lee KE: The changes in visual acuity in a population: the Beaver Dam Eye Study. *Ophthalmology* 103:1169–1178, 1996
16. Klein R, Klein BEK: *The Beaver Dam Eye Study Manual of Operations*. Springfield, VA, U.S. Department of Commerce, 1991 (NTIS accession no. PB91–149823, AS)
17. Klein R, Klein BEK: *The Beaver Dam Eye Study II Manual of Operations*. Springfield, VA, U.S. Department of Commerce, 1995 (NTIS accession no. PB95–273827)
18. Allain CC, Poon LS, Chan CGS, Richmond W, Fu PC: Enzymatic determination of total serum cholesterol. *Clin Chem* 20:470–475, 1994
19. Lopes-Virella MR, Stone P, Ellis S, Colwell JA: Cholesterol determination in high-density lipoproteins separated by three different methods. *Clin Chem* 23:882–884, 1977
20. Klenk DC, Hermanson GT, Krohn RI, Fujimoto EK, Mallia AK, Smith PK, England JD, Wiedmeyer HM, Little RR, Goldstein DE: Determination of glycosylated hemoglobin by affinity chromatography; comparison with colorimetric and ion-exchange methods and effects of common interferences. *Clin Chem* 28:2088–2094, 1982
21. Fossati P, Prencipe L, Berti G: Use of 3, 5-dichloro-2-hydroxybenzenesulfonic acid/4-aminophenazole chromogenic system in direct enzymic assay of uric acid in serum and urine. *Clin Chem* 26:222–231, 1980
22. Stein MW: D-glucose determination with hexokinase and glucose-6-phosphate dehydrogenase. In *Methods of Enzymatic Analysis*. Bergmeyer HC, Ed. New York, Academic Press, 1963
23. Mantel N: Chi-square tests with one degree of freedom: extensions of the Mantel-Haenszel procedure. *J Am Stat Assoc* 58:690–700, 1963
24. Zimmet PZ: Kelly West Lecture 1991: Challenges in diabetes epidemiology: from West to the rest (Review Article). *Diabetes Care* 15:232–252, 1992
25. The Diabetes Prevention Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med* 346:393–403, 2002
26. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Executive Summary. Washington, DC, U.S. Govt. Printing Office, 2001 (NIH publ. no. 01–3670)